John Carroll

Biography for John Carroll

John D. Carroll is a biotech analyst with 34 years of prize-winning experience in journalism. Appointed editor of FierceBiotech in 2003, he has covered genomics, biotechnology, healthcare and other business topics for Managed Care, American Banker, Small Times, and Local Business.com, He has also contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and other leading publications. He spent six years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times. He enjoys hiking, traveling and spending time with his family. Carroll is based in Vermont and Texas and can be reached at john@fiercemarkets.com. Follow @JohnCFierce on Twitter.

Articles by John Carroll

Little Lexicon posts positive diabetes data as rival pharma giants race ahead

The newly downsized Texas-based Lexicon Pharmaceuticals says it nailed promising data on its experimental diabetes drug, positioning it for a late-stage study that could leave it poised to compete with a full lineup of rival treatments already brought to the market by a group of pharma giants.

Roche adds a slate of PhIII schizophrenia trial failures to bitopertin's obituary

A few months ago Roche put out the word that its schizophrenia drug bitopertin had flunked the first two Phase III studies in a lengthy lineup of clinical trials. And today the pharma giant almost completed its obituary for a drug program that had been touted as one of Roche's top blockbuster prospects, adding a long slate of trial flops to the record.

NeoStem strikes deal to acquire California Stem Cell

NeoStem says it will acquire California Stem Cell and a Phase III-ready cancer immunotherapy.

Novartis slams the brakes on once-ambitious RNAi development efforts

Novartis is shuttering a large part of its once-ambitious RNAi research effort in Boston, FierceBiotech has learned. The pharma giant, which has extensive research operations in the Boston area, confirmed the decision, saying that the lingering problems associated with delivering these therapies tied to the small number of relevant targets they could shoot for drove the move.

J&J axes a late-stage Botox rival, chopping project staffers

J&J says that it is discontinuing work on the neurotoxin program for PurTox, its long-acting successor to Botox, even though its Mentor subsidiary has wrapped three late-stage studies on the aesthetic therapy for smoothing out facial wrinkles.

J&J teams with Scripps on a new Big Pharma/biotech spinoff matchmaking effort

Scripps' two big research outfits in California and Florida have allied themselves with the J&J Innovation Center in Menlo Park, CA, in an effort designed to take some of their early-stage breakthroughs and spin off new development programs, looking to kick-start a few biotech startups and Big Pharma match-ups along the way.

Cytos hits the self-destruct button as PhIIb asthma study bombs

After 19 years of fruitless drug development work capped by the failure of a Phase IIb study of its experimental asthma therapy, Cytos Biotechnology is ready to call it quits.

Intercept grabs the spotlight at EASL, builds case for lead drug OCA

Investigators for Intercept Pharmaceuticals spelled out the impact of its lead therapy on rare cases of a liver disease called primary biliary cirrhosis (PBC), fleshing out the results of a late-stage study that it will use to seek U.S. and European approvals later in the year.

VCs gamble $45M on PhII pain drug, new U.S. base for Spinifex

An Australian biotech company with a mid-stage pain drug is using a new $45 million venture round from a group that includes a pair of marquee international investors to put down U.S. roots in Stamford, CT, as it pushes ahead in the clinic. The Series C brings Spinifex Pharmaceuticals' total raise to $70 million, says CEO Tom McCarthy, with enough money committed to fund operations for the next three years.

Cerulean stumbles with IPO as investors fret over biotech stocks

Adamas Pharmaceuticals had to price its IPO at the low end of the range today, then saw the stock price surge in early trading. But the lingering damage of a failed Phase IIb study could be seen when Cerulean stumbled onto the IPO stage after cutting its share price to a mere $7, well below the $11 to $13 range that had been hoped for.